Clinical Trials
14 trialsNCT03081858 2025-06-27
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Phase 1/2 Completed
NCT02783300 2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1 Completed
NCT03219333 2024-08-27
EV-201
Astellas Pharma Inc
Phase 2 Completed
NCT02928406 2024-04-04
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Hoffmann-La Roche
Phase 3 Completed
NCT02603432 2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3 Completed
NCT03636256 2023-08-14
Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT03210376 2020-11-25
Neuromuscular Blockade on Shoulder Pain of Elderly
M.D. Anderson Cancer Center
Phase 4 Completed
NCT02780687 2020-11-18
LUX-Bladder 1
Boehringer Ingelheim
Phase 2 Completed
NCT03138967 2020-09-22
Investigation of Sugammadex in Outpatient Urological Procedures
M.D. Anderson Cancer Center
Phase 4 Completed
NCT00751140 2017-05-30
Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT00350025 2017-03-31
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02006667 2015-02-11
A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00374868 2010-11-04
Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
Eli Lilly and Company
Phase 1/2 Completed